ARCHIVES

Combined analysis moves Herceptin to adjuvant setting in breast cancer.

This article is from The Cancer Letter archive.

Vol. 31 No. 21 | May 27, 2005

Download PDF Visit The Full Archive

Related Articles

Phase II Trial of BIND-014 Shows Anti-Tumor Activity in Q3W Arm

November 28, 2014

FDA To Expand Disclosure For Advisory Committee Members

April 23, 2010

Tobacco Council Awards New Grants

April 18, 1980

DOD Funds 17 Ovarian Cancer Research Grants.

June 20, 2003

Southwest Oncology Group Becomes “SWOG”

April 8, 2011

Grantees Seek $433.5 Million for construction

November 17, 1978